research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
Search
for
Sort by
Research
30 / 1000+ results 
research Hair Aging Revisited: An Expert Delphi Consensus on Pathogenesis, Clinical Features, and Future Therapies
Experts agree on understanding hair aging to improve diagnosis and treatments.
research What’s new in the treatment of hair loss?
New treatments for hair loss, like JAK inhibitors, PRP, anti-androgens, and minoxidil, offer better options.
research Novel investigational drugs for alopecia areata and future perspectives
JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
research Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia
Finasteride and dutasteride are effective in treating male hair loss but can cause sexual side effects and birth defects.
research Psychosocial and Occupational Burden on Caregivers of Adolescents With Alopecia Areata in Australia
Caregivers of teens with alopecia areata face significant mental and work-related challenges.
research Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise
Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.
research The Dermatology Life Quality Index (DLQI ) used as the benchmark in validation of 101 quality‐of‐life instruments: A systematic review
The DLQI is a key tool for measuring quality of life in dermatology.
research Questionnaire Modifications and Alternative Scoring Methods of the Dermatology Life Quality Index: A Systematic Review
There is a significant need for better-validated quality of life tools in dermatology.
research Dimensionality and psychometric analysis of DLQI in a Brazilian population
The DLQI is reliable but may not fully capture the impact of skin conditions on quality of life, especially in emotional and psychological areas.
research A Systematic Review of 207 Studies Describing Validation Aspects of the Dermatology Life Quality Index
The Dermatology Life Quality Index is reliable and consistent but needs more diverse participant studies.
research Skin Lesions in a Daclizumab-treated Patient with Multiple Sclerosis
A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.
research Daclizumab
Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.
research SLAGANJE DVA INSTRUMENTA ZA OCENU KVALITETA ŽIVOTA U DERMATOLOGIJI
Using both DLQI and Skindex-16 together gives a better understanding of quality of life in skin disease patients.
research 24 ARQ-234: a high affinity CD200-Fc fusion protein for the treatment of atopic dermatitis
ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
research Topical application of dehydroxymethylepoxyquinomicin improves allergic inflammation via NF-κB inhibition
A new cream, DHMEQ, reduces allergic skin inflammation effectively.
research 575 INTASYL self-delivering RNAi: A flexible platform to treat dermatological malignancies
INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
research 1114 Study of long-term (15-day) imiquimod treatment and drug intervention in localized psoriasiform dermatitis model
Long-term Imiquimod treatment causes initial skin inflammation that lessens over time, and topical corticosteroids reduce this inflammation and cytokines in a mouse model of psoriasis.
research A newer approach in the treatment of seborrheic dermatitis with QR678® and QR678 Neo®—A prospective pilot study
QR678 Neo® improved seborrheic dermatitis symptoms in a small group of patients.
research LB793 A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
research A Concept on The Development of The DRDE Series of Compounds for Skin Diseases Using In-Silico ADME And Drug-Likeness Analysis
DRDE-07 shows promise for treating skin diseases due to its favorable properties.
research 1112 An innovative phase 1b trial demonstrating proof-of-pharmacology for two novel IRAK4-inhibitors using a local (Imiquimod) and systemic (LPS) driven immune response
Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.
research Novel Quinazoline Derivative Induces Differentiation of Keratinocytes and Enhances Skin Barrier Functions against Th2 Cytokine-Mediated Signaling
SH-340 may improve skin barrier and help treat atopic dermatitis.
research Responsiveness of the DLQI and the Colombian validated version of the Skindex-29 in scarring and non-scarring alopecia
Telogen effluvium most affects quality of life in alopecia patients.
research Dermatology life quality index in patients with persisting and recurrent dermatophytoses
Fungal skin infections significantly lower patients' quality of life.
research Monovalent antibody-conjugated lipid-polymer nanohybrids for active targeting to desmoglein 3 of keratinocytes to attenuate psoriasiform inflammation
The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
research LB1256 TRIV-509, a dual inhibitor of KLK5 and KLK7, rapidly improves barrier integrity and markers of epidermal differentiation in atopic dermatitis skin explants
TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
research 43755 Rapid Reduction and Strict Complete Response in Itch With Oral Difelikefalin in Subjects With Notalgia Paresthetica and Moderate-to-Severe Pruritus
Oral difelikefalin significantly reduces itch in notalgia paresthetica.
research Tralokinumab as a therapeutic option for patients with concurrent atopic dermatitis and alopecia areata
research 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
Dupilumab is effective and safe for treating moderate-to-severe atopic dermatitis in adolescents.